Oncolytics Biotech (Oncolytics Biotech) Cash-to-Debt : 82.61 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Oncolytics Biotech's cash to debt ratio for the quarter that ended in Dec. 2023 was 82.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Oncolytics Biotech could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Oncolytics Biotech's Cash-to-Debt or its related term are showing as below:

ONCY' s Cash-to-Debt Range Over the Past 10 Years
Min: 27.96 Med: 5043.08 Max: No Debt
Current: 82.53

During the past 13 years, Oncolytics Biotech's highest Cash to Debt Ratio was No Debt. The lowest was 27.96. And the median was 5043.08.

ONCY's Cash-to-Debt is ranked better than
77.26% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs ONCY: 82.53

Oncolytics Biotech Cash-to-Debt Historical Data

The historical data trend for Oncolytics Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

27.98

77.87

62.96

86.03

82.61

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															86.03	52.38	50.91	77.76	82.61

Competitive Comparison

For the Biotechnology subindustry, Oncolytics Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Cash-to-Debt falls into.

Oncolytics Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Oncolytics Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	26.023	/	(0.099	+	0.216)
	=	82.61

Oncolytics Biotech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	26.023	/	(0.099	+	0.216)
	=	82.61

Oncolytics Biotech (NAS:ONCY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Oncolytics Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.